Oral News and Research

RSS

Even minor weight loss can improve men’s sex lives: Study

The team of Australian researchers placed 31 obese men with type 2 diabetes on either a meal replacement-based low-calorie diet or a low-fat, high-protein, reduced-carbohydrate diet meant to decrease calorie intake by 600 calories a day. A modest weight loss of 5 percent led to an easing of erectile dysfunction and improved sexual desire within eight weeks, and these improvements continued for 12 months, according to the study published Aug. 5 in The Journal of Sexual Medicine. Problems with urinary tract function also improved, the team added.

8 Aug 2011

Weight loss linked to improved sexual health in obese men with type 2 diabetes

A new study published in The Journal of Sexual Medicine reveals that in obese men with type 2 diabetes, weight loss improves erectile function, sexual desire and lowers urinary tract symptoms.

6 Aug 2011

VIVUS announces additional data from phase 3 QNEXA studies on obesity

VIVUS, Inc. today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV.

6 Aug 2011

Dermatologist discusses common skin conditions that affect people of color at AAD 2011 meeting

The U.S. Census Bureau predicts that by the year 2050, more than half the U.S. population will have skin of color. Recognizing this trend, dermatologists are educating the public about the different ways that common skin conditions appear in various skin tones.

5 Aug 2011

P&G fourth quarter net sales increase 10% to $20.9 billion

The Procter & Gamble Company net sales grew 10 percent to $20.9 billion for the fourth quarter and five percent to $82.6 billion for fiscal 2011.

5 Aug 2011

Appeals court tosses out health challenge brought by New Jersey docs

A U.S. appeals court rejected a bid by group of New Jersey doctors to reinstate their lawsuit challenging the federal health-insurance overhaul. New Jersey Physicians Inc., a nonprofit group, and an uninsured patient identified only as "Patient Roe" failed to adequately plead a concrete or actual injury, the U.S. Court of Appeals in Philadelphia ruled today.

5 Aug 2011

ArQule second quarter net loss increases to $10,804,000

ArQule, Inc. today announced its financial results for the second quarter of 2011.

4 Aug 2011

Boston Therapeutics files chewable metformin ANDA with FDA to treat diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, today announced that it has submitted an Abbreviated New Drug Application (ANDA) for chewable metformin with the U.S. Food and Drug Administration.

4 Aug 2011

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011

Bad teeth in Ozzie kids worries dental health experts

According dental health experts, changes in diet, un-flouridated bottled water and the habit of “constantly bathing” ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Alcohol, tobacco use increase risk of upper aero-digestive tract cancers

Upper aero-digestive tract cancers (UADT), especially those of the oral cavity, pharynx, and larynx, are often referred to as alcohol-related cancers as it has been shown repeatedly that heavy drinkers, in particular, are at increased risk.

3 Aug 2011

N.Y. brothers make good money running nonprofit group to help disabled; Fla. sends Medicaid plan to feds

The New York Times details a the expensive lifestyle of two men from Brooklyn who earned nearly $1 million a year when running a Medicaid-financed nonprofit organization serving the developmentally disabled. Meanwhile, in Florida, state officials submitted their plans for converting Medicaid to a managed care program.

3 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

2 Aug 2011

Rigel reports net loss of $21.5 million for second quarter 2011

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2011.

2 Aug 2011

Coast Dental acquires SmileCare

Coast Dental Services, Inc., has completed the acquisition of the assets of Dental Technology, Inc. (DTI), doing business as SmileCare, and Community Dental Services, Inc., a California licensed health care service plan.

2 Aug 2011

Teva's ZOELY oral contraceptive receives EU Marketing Authorization

Teva Pharmaceutical Industries Ltd announced today that its new oral contraceptive, ZOELY, has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy.

2 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011